MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide
MIRA reports significant weight and fat reduction with oral SKNY-1 in obese mice, with favorable lean-mass and weight-regain outcomes versus semaglutide.